Monoclonal antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions.   Twist Bioscience is on a mission to support this work, offering a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform. Watch the video  to:   Learn about the Hyperimmune Library for therapeutic development against virtually any target. Hear how the latest libraries are opening new sequence space, allowing researchers to focus on difficult-to-drug targets like GPCRs and ion channels. Review recent work from Twist Biopharma using the Library of Libraries against human ACE2 and the SARS-CoV-2 spike protein to find potently neutralizing candidate antibodies against the SARS-CoV-2 strain of coronavirus in under 4 weeks. Compare options for accessing the Library of Libraries, including licensing or partnering to fully outsource lead discovery.

Biopharma

Listen to this special Dr. GPCR podcast featuring Dr. Aaron Sato, CSO, Twist Bioscience. In this Q & A session with Dr. Sato, hosted by Dr. Yamina Berchiche, you will learn how Twist Bioscience’s proprietary technology to manufacture DNA at a scale, has enabled the Twist Biopharma team to tackle the challenge of identifying novel functional antibodies targeting GPCRs by incorporating these natural binding partners into Twist’s antibody library design.